Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy

Abstract

Management of hemophilia has evolved significantly in the last century—from recognition of the causative mechanism in the 1950s to commercially available clotting factor concentrates in the 1960s. Availability of lyophilized concentrates in the 1970s set the stage for home-based therapy, followed by introduction of virally attenuated plasma-derived, and then recombinant factor concentrates in the 1980s and 1990s, respectively. The subsequent years saw a paradigm shift in treatment goals from on-demand therapy to prophylactic factor replacement starting at an early age, to prevent hemarthrosis becoming the standard of care for patients with severe hemophilia. In the developed world, the increasing use of home-based prophylactic regimens has significantly improved the quality of life, and life expectancy of patients with severe hemophilia. Seminal developments in the past 5 years, including the commercial availability of extended half-life factor concentrates and the publication of successful results of gene therapy for patients with hemophilia B, promise to further revolutionize hemophilia care over the next few decades. In this review, we summarize the evolution of management for hemophilia, with a focus on extended half-life factor concentrates and gene therapy.

Keywords

hemophilia - prophylaxis - gene therapy

• References

• 1 Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18 (3) e91-e94
• 2 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16 (1) 20-32
• 3 Kumar R, Carcao M. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am 2013; 60 (6) 1419-1441
• 4 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379 (9824) 1447-1456
• 5 Berntorp E. History of prophylaxis. Haemophilia 2013; 19 (2) 163-165
• 6 Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol 2015; 169 (6) 777-786
• 7 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77) 3-132
• 8 Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-242
• 9 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
• 10 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (5) 571-576
• 11 Schramm W. The history of haemophilia—a short review. Thromb Res 2014; 134 (Suppl. 01) S4-S9
• 12 Otto JC. An account of an hemorrhagic disposition existing in certain families. Clin Orthop Relat Res 1996; (328) 4-6
• 13 Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
• 14 Stevens RF. The history of haemophilia in the royal families of Europe. Br J Haematol 1999; 105 (1) 25-32
• 15 Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK. Genotype analysis identifies the cause of the “royal disease.”. Science 2009; 326 (5954) 817
• 16 Patek AJ, Taylor FH. Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 1937; 16 (1) 113-124
• 17 Biggs R, Douglas AS, MacFarlane RG, Dacie JV, Pitney WR , Merskey. Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952; 2 (4799) 1378-1382
• 18 Biggs R. Thirty years of haemophilia treatment in Oxford. Br J Haematol 1967; 13 (4) 452-463
• 19 Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312
• 20 Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program; 2002: 1-9
• 21 Baxter T, Black D, Birks D. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1998; 351 (9102) 600-601
• 22 White II GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320 (3) 166-170
• 23 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65 (2) 129-135
• 24 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1) 25-32
• 25 Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105 (4) 1109-1113
• 26 Fischer K, van der Bom JG, Mauser-Bunschoten EP , et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99 (7) 2337-2341
• 27 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (4) 700-710
• 28 Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?—The German experience. Haemophilia 1998; 4 (4) 413-417
• 29 Berntorp E, Boulyjenkov V, Brettler D , et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73 (5) 691-701
• 30 Richards M, Williams M, Chalmers E , et al; Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149 (4) 498-507
• 31 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
• 32 Berntorp E, Halimeh S, Gringeri A, Mathias M, Escuriola C, Pérez R. Management of bleeding disorders in children. Haemophilia 2012; 18 (Suppl. 02) 15-23
• 33 Valentino LA, Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev 2011; 25 (1) 11-15
• 34 Feldman BM, Pai M, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (6) 1228-1236
• 35 Hilliard P, Zourikian N, Blanchette V , et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013; 11 (3) 460-466
• 36 Kraft J, Blanchette V, Babyn P , et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10 (12) 2494-2502
• 37 van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130 (1) 107-112
• 38 Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8 (1) 83-89
• 39 Manco-Johnson MJ, Sanders J, Ewing N, Rodriguez N, Tarantino M, Humphries T ; TEEN/TWEN Study Group. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia 2013; 19 (5) 727-735
• 40 Manco-Johnson MJ, Kempton CL, Reding MT , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11 (6) 1119-1127
• 41 Carcao M. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates—what is the real potential benefit?. Haemophilia 2015; 21 (3) 297-299
• 42 Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 01) 19-26 , discussion 26
• 43 Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012; 18 (5) 760-765
• 44 Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18 (4) 568-574
• 45 Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7 (4) 392-396
• 46 Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015; 169 (6) 768-776
• 47 Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014; 20 (Suppl. 04) 99-105
• 48 Shapiro AD, Ragni MV, Kulkarni R , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014; 12 (11) 1788-1800
• 49 Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005; 15 (1) 5-9
• 50 Shapiro AD, Ragni MV, Valentino LA , et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119 (3) 666-672
• 51 Powell JS, Pasi KJ, Ragni MV , et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
• 52 Powell J, Shapiro A, Ragni M , et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol 2015; 168 (1) 113-123
• 53 Powell JS, Apte S, Chambost H , et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2015; 168 (1) 124-134
• 54 Fischer K, Kulkarni R, Bradbury M , et al. Pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B: an interim analysis of the Kids B-LONG Study. Blood 2013; 122 (21)
• 55 Fischer K, Kulkarni R, Nolan B , et al. Safety, efficacy and pharmacokinetics of recombinant factor IX FC fusion protein in children with haemophilia B (KIDS B-LONG). J Thromb Haemost 2015; 13: 87-87
• 56 Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118 (10) 2695-2701
• 57 Collins PW, Young G, Knobe K , et al; paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124 (26) 3880-3886
• 58 Carcao M, Zak M, Karim FA , et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients. Blood 2014; 124 (21)
• 59 Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102 (4) 634-644
• 60 Santagostino E, Negrier C, Klamroth R , et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120 (12) 2405-2411
• 61 Martinowitz U, Lissitchkov T, Lubetsky A , et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 2015; 21 (6) 784-790 . doi:10.1111/hae.12721
• 62 Santagostino E, Jacobs IC, Voigt C, Feussner A, Limsakun T. Pharmacokinetic results of two phase III clinical studies of coagulation factor ix (recombinant) albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP). Blood 2014; 124 (21)
• 63 Powell JS, Josephson NC, Quon D , et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119 (13) 3031-3037
• 64 Mahlangu J, Powell JS, Ragni MV , et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (3) 317-325
• 65 Young G, Mahlangu J, Kulkarni R , et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13 (6) 967-977
• 66 Tiede A, Brand B, Fischer R , et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11 (4) 670-678
• 67 Giangrande P, Chowdary P, Enhrenforth S , et al. Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A—results of pathfinder (TM) 2 international trial. J Thromb Haemost 2015; 13: 176-176
• 68 Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12 (4) 488-496
• 69 Boggio LN, Hong W, Wang M, Eyster ME, Michaels LA. Bleeding Phenotype with Various Bay 94–9027 Dosing Regimens: Subanalyses from the Protect VIII Study. Blood 2014; 124 (21)
• 70 Turecek PL, Bossard MJ, Graninger M , et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 (Suppl. 01) S29-S38
• 71 Konkle BA, Stasyshyn O, Chowdary P , et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (9) 1078-1085
• 72 Schmidbauer S, Witzel R, Robbel L , et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res 2015; 136 (2) 388-395
• 73 Mahlangu J, Kuliczkowski K, Stasyshyn O , et al. RVIII-SingleChain, results of the pivotal phase I/III PK, efficacy and safety clinical trial in adults and adolescents with severe hemophilia A. J Thromb Haemost 2015; 13: 86-86
• 74 Khayat CD, Mahlangu J, Leisinger C , et al. Efficacy and safety of RVIII-SingleChain in surgical prophylaxis. J Thromb Haemost 2015; 13: 602-602
• 75 Lheriteau E, Davidoff AM, Nathwani AC. Haemophilia gene therapy: progress and challenges. Blood Rev 2015; 29 (5) 321-328
• 76 Knobe K, Berntorp E. New treatments in hemophilia: insights for the clinician. Ther Adv Hematol 2012; 3 (3) 165-175
• 77 Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood 1984; 63 (2) 451-456
• 78 Wang L, Zoppè M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94 (21) 11563-11566
• 79 Armstrong EP, Malone DC, Krishnan S, Wessler MJ. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ 2014; 17 (11) 798-802
• 80 Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost 2013; 11 (Suppl. 01) 99-110
• 81 McIntosh J, Lenting PJ, Rosales C , et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121 (17) 3335-3344
• 82 Nathwani AC, Nienhuis AW, Davidoff AM. Our journey to successful gene therapy for hemophilia B. Hum Gene Ther 2014; 25 (11) 923-926
• 83 Nathwani AC, Reiss UM, Tuddenham EGD , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
• 84 Nathwani AC, Tuddenham EGD, Rangarajan S , et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 (25) 2357-2365
• 85 Powell JS, Ragni MV, White II GC , et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102 (6) 2038-2045
• 86 Qiu X, Lu D, Zhou J , et al. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chin Med J (Engl) 1996; 109 (11) 832-839
• 87 Roth DA, Tawa Jr NE, O'Brien JM, Treco DA, Selden RF ; Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344 (23) 1735-1742
• 88 Roth DA, Tawa NE, Proper J , et al. Implantation of non-viral ex vivo genetically modified autologous dermal fibroblasts that express B-domain deleted human factor VIII in 12 severe hemophilia A study subjects. Blood 2002; 100 (11) 116a-117a
• 89 Gansbacher B ; European Society of Gene Therapy; Position of the European Society of Gene Therapy (ESGT). Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). J Gene Med 2003; 5 (3) 261-262
• 90 Hacein-Bey-Abina S, von Kalle C, Schmidt M , et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348 (3) 255-256
• 91 Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost 2015; 13 (Suppl. 01) S133-S142
• 92 Kay MA, Manno CS, Ragni MV , et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24 (3) 257-261
• 93 Manno CS, Chew AJ, Hutchison S , et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101 (8) 2963-2972
• 94 High KA, Manno CS, Sabatino DE , et al. Immune responses to AAV and to factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B. Blood 2003; 102 (11) 154a-155a
• 95 Davidoff AM, Ng CYC, Zhou JF, Spence Y, Nathwani AC. Administration of adenovirus months after transduction of the liver by recombinant adeno-associated virus (rAAV) significantly enhances stable rAAV transgene expression by mechanism independent of second strand synthesis. Mol Ther 2003; 7 (5) S45-S45
• 96 Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99 (18) 11854-11859
• 97 Grimm D, Zhou S, Nakai H , et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102 (7) 2412-2419
• 98 High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia 2014; 20 (Suppl. 04) 43-49
• 99 Mimuro J, Mizukami H, Shima M , et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol 2014; 86 (11) 1990-1997
• 100 Oldenburg J, Albert T. Novel products for haemostasis—current status. Haemophilia 2014; 20 (Suppl. 04) 23-28
• 101 Powell JS. Lasting power of new clotting proteins. Hematology Am Soc Hematol Educ Program 2014; 2014 (1) 355-363
• 102 Kitazawa T, Igawa T, Sampei Z , et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
• 103 Lillicrap D. A complex substitute: antibody therapy for hemophilia. Nat Med 2012; 18 (10) 1460-1461
• 104 Muto A, Yoshihashi K, Takeda M , et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014; 12 (2) 206-213
• 105 Shima M. The potential of bispecific antibodies for treatment of hemophilia A. J Thromb Haemost 2015; 13: 5-6
• 106 Shima M, Hanabusa H, Taki M , et al. Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study. J Thromb Haemost 2015; 13: 6-7
• 107 Hilden I, Lauritzen B, Sørensen BB , et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119 (24) 5871-5878
• 108 Petersen LC. Hemostatic properties of a TFPI antibody. Thromb Res 2012; 129 (Suppl. 02) S44-S45
• 109 Gissel M, Orfeo T, Foley JH, Butenas S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 2012; 130 (6) 948-955
• 110 Gu JM, Ho E, Zhao XY , et al. Pharmacodynamics and pharmacokinetics of TFPI-neutralizing antibody (BAY1093884) in cynomolgus monkeys and prediction of human dose. J Thromb Haemost 2015; 13: 7-7
• 111 Waters EK, Sigh J, Ezban M, Hilden I. Thrombin generation is increased in plasma from healthy males who have received concizumab, an antibody against tissue factor pathway inhibitor (ExplorerTM2). J Thromb Haemost 2015; 13: 7-7
• 112 Kumar R, Chan AKC, Dawson JE, Forman-Kay JD, Kahr WH, Williams S. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol 2014; 166 (1) 130-139
• 113 Sehgal A, Barros S, Ivanciu L , et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (5) 492-497